![Page 1: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/1.jpg)
Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease
Hasan Orhan AKMAN , PhD. William J Craigen, Md PhD.
Salvatore DiMauro, MD
![Page 2: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/2.jpg)
Polyglucosan Body (PGB)
• Polyglucosan (PG) is the polymer of glucose molecules, however, unlike glycogen due to none or poor branching it is insoluble showing starch like properties.
• PG accumulates in the cytosol and forms large aggregates known as PGB. They are visible after diastase digestion and PAS staining.
![Page 3: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/3.jpg)
Polyglucosan Accumulates in the Axons and Cells.
Klein et al. Muscle Nerve. 2004 Feb;29(2):323-8
![Page 4: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/4.jpg)
Molecular Mechanisms for Poor Branching;
• Skewed ratio of glycogen synthase vs.branching activity (GS/GB).
• PFK deficiency
Normal Glycogen
Polyglucosan
![Page 5: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/5.jpg)
PGB Disease Caused By GBE Deficiency has Different Variants Based on Residual Enzyme Activity
Andersen Disease Complete Loss of Enzyme Activity– Lethal in infantile
– Decrease in fetal movements and hydromnios
– Liver and neuromuscular problems
Juvenile form with low Activity – Mainly Liver and Heart,
Adult PGB Disease (APBD) 20% or Less Residual Activity – Muscle weakness,
– Loss of sensation
– Muscles wasting in the arms and/or legs.
– Impaired bladder control (neurogenic bladder)
– Mental confusion (dementia very rare component of APBD)
![Page 6: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/6.jpg)
Targeting Vector
5’ ARM 2.1 kb PGK-Neomycin 3’ARM 6.5 kb Exon 7
Y329S TAT to TCTTyr Ser
FRT
LoxP
Exon 7Intron 6 Intro n 7
Exon 7 PGK-Neo
Exon 7 PGK-Neo ?
Exon 7
Exon 7
Cre Recombination and Excision
Flpe Recombination and Excision of Exon 7 in mouse genome
Intron 6 Intron 7
Gbe1neo
Gbe1Y329S
Gbe1del
![Page 7: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/7.jpg)
Effect of Selection cassette on the progress of the disease
![Page 8: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/8.jpg)
Relative Activity of GBE in Gbe1Neo/Neo
Tissue Genotype % Value % SD n=5
BrainWT 100 2
Flox/Flox 2 42
HeartWT 100 16
Flox/Flox 16 11
LiverWT 100 6
Flox/Flox 6 28
MuscleWT 100 7
Flox/Flox 7 11
KidneyWT 100 1
Flox/Flox 0 NA
![Page 9: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/9.jpg)
Physical Activity (4 months of age)
0.0
100.0
200.0
300.0
400.0
Control GBE1
Av
era
ge
dis
tan
ce
ru
n (
me
ter)
*
Dis
tance r
un (
mete
rs)
![Page 10: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/10.jpg)
Heart
![Page 11: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/11.jpg)
Muscle
![Page 12: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/12.jpg)
Liver
3 weeks old liver
4 month old liver
![Page 13: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/13.jpg)
Brain
![Page 14: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/14.jpg)
PGB in Axons and Cell Body
![Page 15: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/15.jpg)
Mouse Skin Fibroblasts have Polyglucosan
![Page 16: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/16.jpg)
Heart
![Page 17: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/17.jpg)
Skeletal MuscleC
ontr
ol
Gbe1
ne
o/n
eo
Gbe1
ne
o/n
eo
Gbe1
ne
o/n
eo
![Page 18: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/18.jpg)
Glucose Metabolism is Altered in Gbe1neo/neo mice
0
50
100
150
200
250
300
350
400
450
0 20 40 60 80 100 120 140 160 180 200
Glu
cose
Co
nce
ntr
atio
n
mg/
dl
Time (minute)
Control
GBE1
*
*
*
![Page 19: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/19.jpg)
Polyglucosan Can Be Used in The Liver During Fasting
*
*p< 0.002
![Page 20: Molecular Characterization of Polyglucosan Body, Cause or Consequence in the Disease](https://reader034.vdocuments.us/reader034/viewer/2022042607/55a73ff01a28ab69018b45ba/html5/thumbnails/20.jpg)
Conclusion These two models are successful mouse models of APBD
These animal models can be used to study
• Molecular characterization of (PGB).(ii) Determine if the PGB cause or consequence in the disease? (iii)Is it possible to digest PGB in the cell or tissue? if possible how it
effects the course of the disease